SV Dementia Discovery Fund (DDF)

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

We are delighted to announce today that Paulo Fontoura is joining our Board as a non-exec-director. Paulo's brings huge breadth and depth of experience in neurological disorders and the development of highly innovative medicines from his time heading up Neuro at Roche. We are looking forwards to working with Paulo as we advance our FAN1 programme for Huntington's towards the clinic and develop our portfolio of first-in-class targets for the huge unmet need in the Neurodegeneration area! https://lnkd.in/e5Uq72gC

We’re excited to announce that Antony Mattessich has been appointed as our new Chief Executive Officer and Board member to steer our next phase of growth.   Antony is an experienced CEO with strong capital markets experience and an impressive track record progressing programs from discovery through clinical development and onto commercial success. He will play a critical role in advancing our next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline. Read the full announcement here: https://lnkd.in/eE7YSVNR #Appointment #Biotech #DrugDiscovery #TPD #TargetedProteinDegradation

As a father, husband, son, and scientist I dream of a world where no neurological disease is beyond our reach, where we don't shy away from targets because they seem too risky. A world where every neurological disease, no matter how tough, is druggable. Today, with the unveiling of Montara Therapeutics, Inc., I hope to contribute to making that dream a reality.  At my previous company, Mitokinin, we worked for nearly a decade to develop a potential disease-modifying treatment for Parkinson's disease. During that process, I learned how difficult it is to generate safe and effective drugs for many of the neurological diseases that millions suffer from worldwide. After Mitokinin was acquired last fall, I knew that I wanted to start a new company to address some of the other tough-to-drug neurological indications, including Alzheimer's disease, brain cancers, and neuropsychiatric indications. When Kevan Shokat, who was my Ph.D. supervisor University of California, San Francisco and scientific co-founder of Mitokinin, came to me with new research from his lab suggesting a pharmacological mechanism to block drugs from working in the periphery, thereby mitigating their adverse side effects, I immediately recognized the impact this could have, not for the treatment of just one or two diseases, but across nearly all neurodegenerative and neurological diseases and brain cancer.  Together, with the help of our other scientific co-founders, Martin Kampmann and Thomas Südhof, a highly experienced team of advisors, as well as nine stellar employees from Mitokinin, we formed Montara Therapeutics to progress this groundbreaking research from bench to bedside, developing safer and more efficacious treatments for various diseases of the brain. Today, we’re thrilled to announce the funding of our seed round. With support from top-tier investors, including SV Dementia Discovery Fund (DDF), Two Bear Capital, KdT Ventures, and Dolby Family Ventures, I believe we have the right ingredients to accomplish our mission, and I’m very excited for what the future has in store for Montara, but most importantly, for patients We look forward to sharing more details in the months to come. Follow Montara Therapeutics, Inc. to stay updated on our progress. Thanks to Amber Tong and Endpoints News for the exclusive!